SignatureFD’s Krystal Biotech KRYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$49.1K Buy
132
+27
+26% +$8.07K ﹤0.01% 1900
2026
Q1
$27.1K Buy
105
+16
+18% +$4.26K ﹤0.01% 2066
2025
Q4
$21.9K Sell
89
-1
-1% -$210 ﹤0.01% 2083
2025
Q3
$15.9K Buy
90
+11
+14% +$1.65K ﹤0.01% 2217
2025
Q2
$10.9K Sell
79
-51
-39% -$7.49K ﹤0.01% 2319
2025
Q1
$23.4K Buy
130
+23
+21% +$3.87K ﹤0.01% 1986
2024
Q4
$16.8K Sell
107
-23
-18% -$4.08K ﹤0.01% 2143
2024
Q3
$23.7K Sell
130
-3
-2% -$578 ﹤0.01% 1958
2024
Q2
$24.4K Buy
133
+33
+33% +$5.54K ﹤0.01% 1865
2024
Q1
$17.8K Buy
100
+3
+3% +$417 ﹤0.01% 2052
2023
Q4
$12K Sell
97
-47
-33% -$5.21K ﹤0.01% 2172
2023
Q3
$16.7K Buy
144
+18
+14% +$2.2K ﹤0.01% 1941
2023
Q2
$14.8K Sell
126
-16
-11% -$1.63K ﹤0.01% 2050
2023
Q1
$11.4K Sell
142
-32
-18% -$2.51K ﹤0.01% 2148
2022
Q4
$13.8K Buy
174
+64
+58% +$4.75K ﹤0.01% 1987
2022
Q3
$8K Buy
110
+8
+8% +$578 ﹤0.01% 2189
2022
Q2
$7K Buy
102
+9
+10% +$560 ﹤0.01% 2305
2022
Q1
$6K Sell
93
-125
-57% -$7.8K ﹤0.01% 2407
2021
Q4
$15K Buy
+218
New +$12.7K ﹤0.01% 1915
2021
Q2
Sell
-53
Closed -$4K 3004
2021
Q1
$4K Buy
+53
New +$3.85K ﹤0.01% 2252
2020
Q3
Sell
-39
Closed -$2K 2685
2020
Q2
$2K Hold
39
﹤0.01% 2136
2020
Q1
$2K Buy
+39
New +$2.04K ﹤0.01% 1956

Other funds holding KRYS

SignatureFD's KRYS Position: Q2 2026 in Review

SignatureFD increased its Krystal Biotech (KRYS) stake by 26% in Q2 2026, buying an estimated $8.07K and bringing the position to 132 shares worth $49.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1900.

SignatureFD first reported a position in KRYS in Q1 2020 and has held it in 22 quarters since. 68 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • SignatureFD held 132 shares of Krystal Biotech worth $49.1K as of Q2 2026.
  • SignatureFD bought 27 Krystal Biotech shares in Q2 2026, an estimated $8.07K.
  • Krystal Biotech made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #1900 holding.
  • SignatureFD first reported a position in Krystal Biotech in Q1 2020 and has held it in 22 quarters since.
  • 68 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.